Literature DB >> 18620458

Modelling approaches: the case of schizophrenia.

Bart M S Heeg1, Joep Damen, Erik Buskens, Sue Caleo, Frank de Charro, Ben A van Hout.   

Abstract

Schizophrenia is a chronic disease characterized by periods of relative stability interrupted by acute episodes (or relapses). The course of the disease may vary considerably between patients. Patient histories show considerable inter- and even intra-individual variability. We provide a critical assessment of the advantages and disadvantages of three modelling techniques that have been used in schizophrenia: decision trees, (cohort and micro-simulation) Markov models and discrete event simulation models. These modelling techniques are compared in terms of building time, data requirements, medico-scientific experience, simulation time, clinical representation, and their ability to deal with patient heterogeneity, the timing of events, prior events, patient interaction, interaction between co-variates and variability (first-order uncertainty). We note that, depending on the research question, the optimal modelling approach should be selected based on the expected differences between the comparators, the number of co-variates, the number of patient subgroups, the interactions between co-variates, and simulation time. Finally, it is argued that in case micro-simulation is required for the cost-effectiveness analysis of schizophrenia treatments, a discrete event simulation model is best suited to accurately capture all of the relevant interdependencies in this chronic, highly heterogeneous disease with limited long-term follow-up data.

Entities:  

Mesh:

Year:  2008        PMID: 18620458     DOI: 10.2165/00019053-200826080-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  38 in total

1.  A meta-analysis of the efficacy of second-generation antipsychotics.

Authors:  John M Davis; Nancy Chen; Ira D Glick
Journal:  Arch Gen Psychiatry       Date:  2003-06

2.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

3.  Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".

Authors:  Jerry D Clewell; Robert W Baker
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

4.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

Review 7.  Time preference for health in cost-effectiveness analysis.

Authors:  J Lipscomb
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

8.  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Authors:  Natalie C Edwards; Marcia F T Rupnow; Chris L Pashos; Marc F Botteman; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Authors:  Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

10.  Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.

Authors:  Montserrat Vera-Llonch; Thomas E Delea; Erin Richardson; Marcia Rupnow; Amy Grogg; Gerry Oster
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

View more
  20 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting.

Authors:  L B Standfield; T A Comans; P A Scuffham
Journal:  Eur J Health Econ       Date:  2015-12-29

3.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Integrative etiopathogenetic models of psychotic disorders: methods, evidence and concepts.

Authors:  Wolfgang Gaebel; Jürgen Zielasek
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

Review 5.  Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies.

Authors:  Huajie Jin; Stewart Robinson; Wenru Shang; Evanthia Achilla; David Aceituno; Sarah Byford
Journal:  Pharmacoeconomics       Date:  2021-05-20       Impact factor: 4.981

6.  Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Authors:  Pudtan Phanthunane; Theo Vos; Harvey Whiteford; Melanie Bertram
Journal:  Cost Eff Resour Alloc       Date:  2011-05-13

Review 7.  A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.

Authors:  Jean-Eric Tarride; Robert Hopkins; Gord Blackhouse; James M Bowen; Matthias Bischof; Camilla Von Keyserlingk; Daria O'Reilly; Feng Xie; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 8.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

9.  The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.

Authors:  Annemieke Leunis; W Ken Redekop; Kees A G M van Montfort; Bob Löwenberg; Carin A Uyl-de Groot
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

Review 10.  Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.